Who owns TSCAN THERAPEUTICS INC?
- Ticker: TCRX
- CUSIP Number: 89854m101
Tip: Access positions for across all investors
Analyze quarterly positions in Tscan Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Tscan Therapeutics stock
Who bought or sold TSCAN THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Lynx1 Capital Management | 5.2M | $42M | 0% | Mar 2024 |
|
| EcoR1 Capital | 5.0M | $40M | 0% | Mar 2024 |
|
| Adage Capital Partners GP | 3.9M | $31M | -2% | Mar 2024 |
|
| BVF | 3.0M | $24M | 0% | Mar 2024 |
|
| Baker Bros. Advisors | 2.8M | $22M | 0% | Mar 2024 |
|
| Propel Bio Management | 2.1M | $17M | 0% | Mar 2024 |
|
| Vanguard Group | 1.8M | $14M | 1% | Mar 2024 |
|
| BlackRock | 1.7M | $14M | 1% | Mar 2024 |
|
| Deer Management | 1.2M | $9.9M | 0% | Mar 2024 |
|
| Alphabet | 1.1M | $8.6M | 0% | Mar 2024 |
|
| Simplify Asset Management | 1.0M | $8.3M | 0% | Mar 2024 |
|
| Geode Capital Management | 414k | $3.3M | 34% | Mar 2024 |
|
| Millennium Management | 392k | $3.1M | 296% | Mar 2024 |
|
| Laurion Capital Management | 363k | $2.9M | 500% | Mar 2024 |
|
| Susquehanna International | 298k | $2.4M | 1661% | Mar 2024 |
|
| Goldman Sachs Group | 260k | $2.1M | 759% | Mar 2024 |
|
| Morgan Stanley | 224k | $1.8M | -14% | Mar 2024 |
|
| Tocqueville Asset Management | 212k | $1.7M | 100% | Mar 2024 |
|
| Standard Life Aberdeen | 200k | $1.6M | 0% | Mar 2024 |
|
| Marshall Wace | 191k | $1.5M | 73% | Mar 2024 |
|
| Jane Street | 153k | $1.2M | 83% | Mar 2024 |
|
| Qube Research & Technologies | 144k | $1.1M | 5856% | Mar 2024 |
|
| Citigroup | 117k | $928k | 60% | Mar 2024 |
|
| Stifel Financial | 101k | $805k | -16% | Mar 2024 |
|
| NewEdge Wealth | 92k | $791k | 0% | Mar 2024 |
|
| Man Group | 77k | $614k | 53% | Mar 2024 |
|
| Northern Trust | 77k | $611k | 7% | Mar 2024 |
|
| Jpmorgan Chase & Co | 67k | $532k | 102% | Mar 2024 |
|
| Bridgeway Capital Management | 63k | $503k | -28% | Mar 2024 |
|
| Walleye Trading Advisors | 53k | $417k | 195% | Mar 2024 |
|
| Marathon Trading Investment Management | 51k | $405k | 100% | Mar 2024 |
|
| Cubist Systematic Strategies | 44k | $352k | 69% | Mar 2024 |
|
| Balyasny Asset Management | 42k | $333k | -9% | Mar 2024 |
|
| Two Sigma Investments | 38k | $300k | 100% | Mar 2024 |
|
| ExodusPoint Capital Management | 36k | $283k | 100% | Mar 2024 |
|
| Hrt Financial | 35k | $276k | 100% | Mar 2024 |
|
| Brevan Howard Capital Management | 35k | $275k | 100% | Mar 2024 |
|
| American Century Companies | 32k | $253k | 66% | Mar 2024 |
|
| Bank of America Corporation | 30k | $240k | -20% | Mar 2024 |
|
| Y-Intercept | 24k | $194k | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 22k | $176k | 0% | Mar 2024 |
|
| Letko, Brosseau & Associates | 21k | $164k | 0% | Mar 2024 |
|
| Point72 Asia | 20k | $157k | 100% | Mar 2024 |
|
| Cannon Global Investment Management | 18k | $139k | 100% | Mar 2024 |
|
| Credit Suisse | 17k | $138k | 100% | Mar 2024 |
|
| Privium Fund Management | 16k | $127k | 0% | Mar 2024 |
|
| Leucadia National Corporation | 12k | $97k | 100% | Mar 2024 |
|
| Citadel Advisors | 11k | $91k | 100% | Mar 2024 |
|
| CTC Alternative Strategies | 11k | $87k | 100% | Mar 2024 |
|
| Cambridge Investment Research Advisors | 10k | $80k | 100% | Mar 2024 |
|
| Aries Wealth Management | 10k | $79k | 0% | Mar 2024 |
|
| Waldron | 10k | $79k | 0% | Mar 2024 |
|
| Lazard Asset Management | 4.0k | $0 | 100% | Dec 2023 |
|
| UBS Group | 1.9k | $15k | 33% | Mar 2024 |
|
| Wells Fargo & Company | 306.00 | $2.4k | 2% | Mar 2024 |
|
| Atlas Capital Advisors | 18.00 | $142.000200 | -98% | Mar 2024 |
|
Who sold out of Tscan Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| 683 Capital Management | Dec 2023 | 43k | $252k |
| Virtu Financial | Dec 2023 | 18k | $107k |
| Bank of New York Mellon | Dec 2023 | 17k | $97k |